Your browser is no longer supported. Please, upgrade your browser.
Tarsus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own17.00% Shs Outstand21.05M Perf Week-18.50%
Market Cap644.34M Forward P/E- EPS next Y-2.62 Insider Trans0.00% Shs Float13.52M Perf Month-18.24%
Income- PEG- EPS next Q-0.66 Inst Own61.70% Short Float2.58% Perf Quarter32.63%
Sales- P/S- EPS this Y-254.10% Inst Trans- Short Ratio3.77 Perf Half Y-
Book/sh- P/B- EPS next Y-14.90% ROA- Target Price41.50 Perf Year-
Cash/sh4.10 P/C7.47 EPS next 5Y- ROE- 52W Range15.32 - 63.69 Perf YTD-25.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.94% Beta-
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low99.74% ATR3.57
Employees12 Current Ratio14.50 Sales Q/Q- Oper. Margin- RSI (14)34.98 Volatility12.37% 10.03%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.47 Prev Close33.13
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume92.49K Price30.61
Recom1.20 SMA20-18.88% SMA50-24.34% SMA200-8.32% Volume43,175 Change-7.61%
Nov-10-20Initiated Raymond James Strong Buy $39
Nov-10-20Initiated Ladenburg Thalmann Buy $42
Nov-10-20Initiated Jefferies Buy $35
Nov-10-20Initiated BofA Securities Buy $33
Jan-19-21 08:30AM  
Jan-18-21 08:43AM  
Jan-07-21 09:24AM  
Jan-05-21 05:00PM  
Dec-23-20 07:00AM  
Dec-21-20 07:00AM  
Nov-19-20 03:24PM  
Nov-13-20 07:35PM  
Oct-20-20 04:05PM  
Oct-16-20 06:05PM  
Oct-15-20 08:35PM  
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.